The Clinical Research On The Treatment Of Phlegm Heat Type Essential Hypertension By Modified Shengjiang Powder Acupoint Application

Objective: By observing the clinical effects of modified Shengjiang Powder acupoint application combined with conventionalwestern medicine on the blood pressure level,TCM syndrome,blood lipids and homocysteine of patients with phlegm heat type hypertension before and after treatment,this project objectively evaluated its efficacy and safety,and provided a new idea for the clinical treatment of essential hypertension.Methods: From October 2018 to October 2019,62 patients whomet the inclusion criteria were selected from the outpatient and inpatient service of the heart disease department of Shijiazhuang City Hospital of traditional Chinese medicine.Rrandomly divided into treatment group and control group,the control group was given amlodipine benzenesulfonic acid tablets orally,while the treatment group was given amlodipine benzenesulfonic acid tablets orally combined with modified Shengjiang Powder acupoint application treatment.Both groups were treated continuously for 4 weeks(2 weeks was a course of treatment,a total of 2 courses of treatment).Changes in blood pressure and TCM syndrome of the two groups of patients before and after treatment were recorded,and blood samples of the two groups were collected to measure and record the levels of blood lipids and homocysteine before and after treatment.SPSS 21.0 statistical method was used to analyze relevant records.To observe the effect of modified Shengjiang Powder acupoint application combined with conventional western medicine on the related indexes of patients with phlegm heat type essential hypertension.Results:(1)Blood pressure: After treatment,both systolic and diastolic blood pressure in the two groups were lower than before treatment,with significant difference between the two groups(P<0.01).The reduction in the treatment group was better than that in the controlgroup,with a significant difference(P<0.01).(2)Blood pressure efficacy: The total effective rate ofblood pressure reduction in the treatment group and the control groupwere 90% and 70.90%,respectively,showing statistical difference between the two groups(P<0.05).(3)Single symptom score: After treatment,except for palpitation(P>0.05),the score of other symptoms in the treatment group were lower than that before treatment(P<0.01).After treatment,except for vertigo and headache(P<0.01),the scores of other symptoms in the control group were not significantly lower than those before treatment(P>0.05).After treatment,except for palpitations,scores of other symptoms in the treatment group were lower than those in the control group,with statistical difference between the two groups(P<0.05).(4)Total score of TCM syndromes: After treatment,the total score of syndromes in the two groups was lower than that before treatment,with a significant difference(P<0.01).The reduction in the treatment group was better than that in the control group,with significant difference between the two groups(P<0.01).(5)Symptom efficacy: The effective rate of symptom in the treatment group and the control group were 90% and 64.50%,respectively,with statistical difference between the two groups(P<0.05).(6)Blood lipid: After treatment,triglyceride(TG)in the treatment group was lower than that before treatment,with a statistical difference(P<0.05).Total cholesterol(TC),low densitylipoprotein cholesterol(LDL-C)and high density lipoprotein cholesterol(HDL-C)were not significantly different from those before treatment(P>0.05).Compared with all indexes in the control group before treatment,there was no significant difference(P>0.05).After treatment,TG in the treatment group was lower than that in the control group,with statistical difference between the two groups(P<0.05),there was no significant difference in other items(P>0.05).(7)Homocysteine(HCY): After treatment,HCY in the treatment group was lower than before treatment,with a statistical difference(P<0.05).HCY in the control group was slightly lower than that before treatment,but there was no statistical difference(P>0.05).After treatment,HCY in the treatment group was lower than that in the control group,with statistical difference between the two groups(P<0.05).(8)Safety observation: No abnormal safety indicators and no adverse reactions were found before and after treatment.Conclusion: Modified Shengjiang Powder acupoint application combined with conventional western medicine in the treatment of phlegm heat type essential hypertension can better reduce the level of blood pressure,improve the clinical symptoms of patients,andregulate the level of blood lipid and homocysteine to a certain extent.There is no adverse reaction in the treatment process,and the clinical application is safe,convenient and effective,which is worthy of further study and extensive promotion.